• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    2/13/24 5:12:22 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGN alert in real time by email
    SC 13G/A 1 tv01627-organonco.htm SCHEDULE 13G/A organonco

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 3)*

    Name of issuer:  Organon & Co

    Title of Class of Securities:  Common Stock

    CUSIP Number:  68622V106

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  68622V106

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    193,134

    7.  SOLE DISPOSITIVE POWER

    30,137,443

    8.  SHARED DISPOSITIVE POWER

    459,265

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    30,596,708

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    11.97%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Organon & Co

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    30 Hudson Street, 33rd floor
    Jersey City, NJ 07302

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    68622V106

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $OGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OGN

    DatePrice TargetRatingAnalyst
    5/2/2025Outperform → In-line
    Evercore ISI
    9/6/2024$18.00 → $20.00Neutral → Underweight
    JP Morgan
    11/3/2023$33.00 → $16.00Buy → Neutral
    Goldman
    9/21/2023$28.00Overweight
    Barclays
    3/16/2023$33.00Outperform
    Raymond James
    10/14/2022$27.00 → $25.00Neutral → Underperform
    BofA Securities
    9/6/2022$37.00 → $34.00Neutral → Overweight
    Piper Sandler
    8/5/2022$40.00 → $37.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $OGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Organon & Co. (Amendment)

      SC 13G/A - Organon & Co. (0001821825) (Subject)

      2/13/24 5:12:22 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Organon & Co. (Amendment)

      SC 13G/A - Organon & Co. (0001821825) (Subject)

      2/5/24 3:47:19 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Organon & Co. (Amendment)

      SC 13G/A - Organon & Co. (0001821825) (Subject)

      1/25/24 12:23:52 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Human Resources Officer Falcione Aaron bought $48,235 worth of shares (5,500 units at $8.77), increasing direct ownership by 10% to 62,974 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:13:47 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gen. Counsel & Corp. Secy. Weaver Kirke bought $74,054 worth of shares (8,045 units at $9.21), increasing direct ownership by 18% to 52,489 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:12:22 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive VP, Corp. Dev. Karp Daniel bought $28,828 worth of shares (3,500 units at $8.24), increasing direct ownership by 8% to 46,669 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:09:34 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Organon Reports Results for the First Quarter Ended March 31, 2025

      Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs in 2025 Vtama on track to achieve $150 million revenue target for full year 2025; double-digit growth in Nexplanon in the first quarter Company resets capital allocation priorities to accelerate progress towards deleveraging; new annual regular dividend rate of $0.08 per share First quarter 2025 revenue of $1.513 billion, down 7% as-reported and down 4% at constant currency, consistent with company's expectation

      5/1/25 7:00:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

      Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

      4/15/25 5:00:00 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

      Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or milestones due to the level of uncertainty and ability to forecast the timing of such achievements. As such, these milestones, as well as any future IPR&D and milestones are not contemplated in the company's financial guidance provided on Feb

      4/15/25 7:31:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Financials

    Live finance-specific insights

    See more
    • Organon Reports Results for the First Quarter Ended March 31, 2025

      Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs in 2025 Vtama on track to achieve $150 million revenue target for full year 2025; double-digit growth in Nexplanon in the first quarter Company resets capital allocation priorities to accelerate progress towards deleveraging; new annual regular dividend rate of $0.08 per share First quarter 2025 revenue of $1.513 billion, down 7% as-reported and down 4% at constant currency, consistent with company's expectation

      5/1/25 7:00:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

      Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or milestones due to the level of uncertainty and ability to forecast the timing of such achievements. As such, these milestones, as well as any future IPR&D and milestones are not contemplated in the company's financial guidance provided on Feb

      4/15/25 7:31:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

      Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE:OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (NASDAQ:BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market, was launched in May 2024 and is indicated in certain patients for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and

      4/1/25 7:30:00 AM ET
      $BIIB
      $OGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $OGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

      Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

      4/15/25 5:00:00 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

      Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel

      3/10/25 12:01:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

      Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women's health. KIRKLAND, QC, Oct. 8, 2024 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, today announced updates to its Canadian leadership team with an appointment and promotion. Effective September 1, 2024, Jeffrey Malawsk

      10/8/24 8:01:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Organon & Co.

      10-Q - Organon & Co. (0001821825) (Filer)

      5/2/25 8:42:12 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon & Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Organon & Co. (0001821825) (Filer)

      5/1/25 7:12:00 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Organon & Co.

      DEFA14A - Organon & Co. (0001821825) (Filer)

      4/25/25 4:40:13 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Human Resources Officer Falcione Aaron bought $48,235 worth of shares (5,500 units at $8.77), increasing direct ownership by 10% to 62,974 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:13:47 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gen. Counsel & Corp. Secy. Weaver Kirke bought $74,054 worth of shares (8,045 units at $9.21), increasing direct ownership by 18% to 52,489 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:12:22 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive VP, Corp. Dev. Karp Daniel bought $28,828 worth of shares (3,500 units at $8.24), increasing direct ownership by 8% to 46,669 units (SEC Form 4)

      4 - Organon & Co. (0001821825) (Issuer)

      5/7/25 12:09:34 PM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Organon downgraded by Evercore ISI

      Evercore ISI downgraded Organon from Outperform to In-line

      5/2/25 8:13:50 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon downgraded by JP Morgan with a new price target

      JP Morgan downgraded Organon from Neutral to Underweight and set a new price target of $20.00 from $18.00 previously

      9/6/24 7:47:49 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organon downgraded by Goldman with a new price target

      Goldman downgraded Organon from Buy to Neutral and set a new price target of $16.00 from $33.00 previously

      11/3/23 7:22:32 AM ET
      $OGN
      Biotechnology: Pharmaceutical Preparations
      Health Care